Find a Clinical Trial

Showing 21 - 30 of 165 Trials

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Principal Investigator:

Benjamin Izar, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07015190

Population:

Adult

Phase:

III

The study drug used in this study is darovasertib. The study drug will be given to you orally (by mouth) if you participate in the study. You should only take the study drug as instructed. Darovasertib is an investigational (experimental) new drug, which means darovasertib has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authorities in the world. Darovasertib blocks a protein in your body called Protein Kinase C (PKC). Approximately 90% of people with uveal melanoma have a genetic mutation in PKC. The tumor may depend on the effects of PKC to...
A Phase 3 Randomized, Double-Blind, Active-ControlledStudy of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2Advanced Breast Cancer (OPERA-02)

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT07085767

Population:

Adult

Phase:

III

Palazestrant (OP-1250) is a pill designed to block and break down estrogen receptors, which are often what help certain breast cancers grow. It is being developed to treat people with a type of breast cancer that is estrogen‑receptor positive (ER+) and human epidermal growth factor receptor 2 (HER2)-negative. This study aims to compare two treatment combinations for people receiving their first treatment for ER+, HER2- breast cancer that has spread or cannot be removed with surgery. The study will look at how safe and effective palazestrant plus ribociclib is compared with letrozole plus...
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT07104032

Population:

Adult

Phase:

III

This clinical trial is being performed to study a drug called tirabrutinib in the treatment of Primary Central Nervous System Lymphoma (PCNSL). PCNSL is a rare cancer that occurs within tissues of the brain, usually without cancerous lesions in other parts of the body. The purpose of this study is to learn how well tirabrutinib (the investigational study drug) works against cancer as compared to the combination of rituximab and temozolomide (comparators) in participants with PCNSL. The study is also being done to learn more about the safety of tirabrutinib and to look at how tirabrutinib may...
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

Principal Investigator:

Monica Kasbekar, MD PHD

Contact Number:

212-342-5162

NCT Number:

NCT07357727

Population:

Adult

Phase:

III

The purpose of this study is to find out whether taking pelabresib together with ruxolitinib works better than taking ruxolitinib alone in adults with myelofibrosis, a rare blood cancer that affects the bone marrow. Ruxolitinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of myelofibrosis, while pelabresib is an investigational drug that has not been approved by the FDA. The study will compare whether the combination treatment can better reduce spleen size and improve myelofibrosis-related symptoms than ruxolitinib alone. Participants will be randomly assigned...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune®(TTFields, 200 kHz) Concomitant with Maintenance Temozolomide andPembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide andPlacebo for the Treatment of Newly

Principal Investigator:

Maria Diaz Ordonez, MD

Contact Number:

212-342-5162

NCT Number:

NCT06556563

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects of pembrolizumab simultaneously with the Optune device and maintenance temozolomide (TMZ) versus placebo simultaneously with Optune and maintenance TMZ for the study treatment of newly diagnosed glioblastoma multiforme (GBM). In this study, a placebo is an inactive substance that looks the same as and is given the same way as pembrolizumab. The effects of pembrolizumab are compared to the effects of the placebo. Pembrolizumab is an immunotherapy and it works with your immune system to help fight cancer. Optune® device generates Tumor...
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Principal Investigator:

Rajshekhar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT03937635

Population:

Adult

Phase:

III

The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period of time in which patients are free of multiple myeloma symptoms differs between the two treatment groups. Daratumumab is already approved by the FDA for use in combination with lenalidomide and dexamethasone in people who have received at...
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

Principal Investigator:

Claire Sathe, MD

Contact Number:

212-342-5162

NCT Number:

NCT06492616

Population:

Adult

Phase:

III

The purpose of this study is to test a new endocrine therapy, called elacestrant, that may stop hormones from attaching to cancer cells and helping them grow. Researchers would like to understand if switching standard treatment to elacestrant (the study drug) will help to slow down or stop the growth of cancer. Treatments for early breast cancer include endocrine therapy, also called hormone therapy. Endocrine therapies work by blocking hormones from reaching the cancer cells or by reducing the amount of hormones the body makes. Are you Eligible? (Inclusion Criteria) Must be 18 years old or...
FURMO-006 // A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced

Principal Investigator:

Catherine Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT07185997

Population:

Adult

Phase:

III

You are being asked to participate in this study because you have a type of lung cancer called non-small-cell lung cancer (NSCLC) that has spread and because it contains certain mutations (changes) in a gene called epidermal growth factor receptor (EGFR). The EGFR mutations lead to cancers in the lung such as NSCLC. This study is for people with uncommon EGFR mutation subtypes where the data for the best treatment is less known due to their rarity. A drug called firmonertinib is being developed for the treatment of NSCLC with mutations in EGFR with a specific change in the P-loop and alpha C-...
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT06671912

Population:

Adult

Phase:

III

This study is being done to answer the following question: Is treatment with a lower dose of tamoxifen, a form of hormonal therapy, as good as the usual hormonal therapy in women with low-risk, early-stage breast cancer? The usual approach for patients who are not in a study is treatment with hormonal therapy. Hormonal therapy can be an aromatase inhibitor (such as letrozole, anastrozole, or exemestane) or tamoxifen at a dose of 20mg/day. Your doctor can explain which treatment may be best for you. For patients who get the usual approach for this cancer, about 96 out of 100 are free of cancer...
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Principal Investigator:

Meghna S Trivedi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05812807

Population:

Adult

Phase:

III

This study is being done to answer the following question: Among patients with early-stage triple-negative breast cancer (TNBC) who achieve a pathologic complete response (pCR) after preoperative chemotherapy in combination with pembrolizumab, will observation after surgery be as effective as completing 6 more months of pembrolizumab after surgery at preventing cancer from coming back? This study aims to find out if observation is as good as the usual approach for early-stage TNBC. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages